156 related articles for article (PubMed ID: 29435981)
1. Forty-nine gastric cancer cell lines with integrative genomic profiling for development of c-MET inhibitor.
Kim HJ; Kang SK; Kwon WS; Kim TS; Jeong I; Jeung HC; Kragh M; Horak ID; Chung HC; Rha SY
Int J Cancer; 2018 Jul; 143(1):151-159. PubMed ID: 29435981
[TBL] [Abstract][Full Text] [Related]
2. Tivantinib inhibits the VEGF signaling pathway and induces apoptosis in gastric cancer cells with c-MET or VEGFA amplification.
Kim BJ; Kim YJ; Sohn SH; Kim B; Sul HJ; Kim HS; Zang DY
Invest New Drugs; 2020 Dec; 38(6):1633-1640. PubMed ID: 32361789
[TBL] [Abstract][Full Text] [Related]
3. MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.
Chen CT; Kim H; Liska D; Gao S; Christensen JG; Weiser MR
Mol Cancer Ther; 2012 Mar; 11(3):660-9. PubMed ID: 22238368
[TBL] [Abstract][Full Text] [Related]
4. Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.
Zaman S; Shentu S; Yang J; He J; Orlowski RZ; Stellrecht CM; Gandhi V
Neoplasia; 2015 Mar; 17(3):289-300. PubMed ID: 25810013
[TBL] [Abstract][Full Text] [Related]
5. Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinoma.
Wei K; Li M; Zöller M; Wang M; Mehrabi A; Hoffmann K
Cell Death Dis; 2019 Mar; 10(3):231. PubMed ID: 30850583
[TBL] [Abstract][Full Text] [Related]
6. Increased HGF Expression Induces Resistance to c-MET Tyrosine Kinase Inhibitors in Gastric Cancer.
Ahn SY; Kim J; Kim MA; Choi J; Kim WH
Anticancer Res; 2017 Mar; 37(3):1127-1138. PubMed ID: 28314274
[TBL] [Abstract][Full Text] [Related]
7. Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks.
Kataoka Y; Mukohara T; Tomioka H; Funakoshi Y; Kiyota N; Fujiwara Y; Yashiro M; Hirakawa K; Hirai M; Minami H
Invest New Drugs; 2012 Aug; 30(4):1352-60. PubMed ID: 21655918
[TBL] [Abstract][Full Text] [Related]
8. The current state of molecularly targeted drugs targeting HGF/Met.
Yano S; Nakagawa T
Jpn J Clin Oncol; 2014 Jan; 44(1):9-12. PubMed ID: 24371262
[TBL] [Abstract][Full Text] [Related]
9. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
[TBL] [Abstract][Full Text] [Related]
10. Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion.
Asaoka Y; Tada M; Ikenoue T; Seto M; Imai M; Miyabayashi K; Yamamoto K; Yamamoto S; Kudo Y; Mohri D; Isomura Y; Ijichi H; Tateishi K; Kanai F; Ogawa S; Omata M; Koike K
Biochem Biophys Res Commun; 2010 Apr; 394(4):1042-6. PubMed ID: 20331976
[TBL] [Abstract][Full Text] [Related]
11. Heat-shock protein 27 (HSP27, HSPB1) is up-regulated by MET kinase inhibitors and confers resistance to MET-targeted therapy.
Musiani D; Konda JD; Pavan S; Torchiaro E; Sassi F; Noghero A; Erriquez J; Perera T; Olivero M; Di Renzo MF
FASEB J; 2014 Sep; 28(9):4055-67. PubMed ID: 24903273
[TBL] [Abstract][Full Text] [Related]
12. Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification.
Okamoto W; Okamoto I; Arao T; Kuwata K; Hatashita E; Yamaguchi H; Sakai K; Yanagihara K; Nishio K; Nakagawa K
Mol Cancer Ther; 2012 Jul; 11(7):1557-64. PubMed ID: 22729845
[TBL] [Abstract][Full Text] [Related]
13. A novel inhibitor of c-Met and VEGF receptor tyrosine kinases with a broad spectrum of in vivo antitumor activities.
Awazu Y; Nakamura K; Mizutani A; Kakoi Y; Iwata H; Yamasaki S; Miyamoto N; Imamura S; Miki H; Hori A
Mol Cancer Ther; 2013 Jun; 12(6):913-24. PubMed ID: 23548264
[TBL] [Abstract][Full Text] [Related]
14. Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models.
Gavine PR; Ren Y; Han L; Lv J; Fan S; Zhang W; Xu W; Liu YJ; Zhang T; Fu H; Yu Y; Wang H; Xu S; Zhou F; Su X; Yin X; Xie L; Wang L; Qing W; Jiao L; Su W; Wang QM
Mol Oncol; 2015 Jan; 9(1):323-33. PubMed ID: 25248999
[TBL] [Abstract][Full Text] [Related]
15. Proliferation Markers Are Associated with MET Expression in Hepatocellular Carcinoma and Predict Tivantinib Sensitivity
Rebouissou S; La Bella T; Rekik S; Imbeaud S; Calatayud AL; Rohr-Udilova N; Martin Y; Couchy G; Bioulac-Sage P; Grasl-Kraupp B; de Koning L; Ganne-Carrié N; Nault JC; Ziol M; Zucman-Rossi J
Clin Cancer Res; 2017 Aug; 23(15):4364-4375. PubMed ID: 28246274
[No Abstract] [Full Text] [Related]
16. Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.
Baltschukat S; Engstler BS; Huang A; Hao HX; Tam A; Wang HQ; Liang J; DiMare MT; Bhang HC; Wang Y; Furet P; Sellers WR; Hofmann F; Schoepfer J; Tiedt R
Clin Cancer Res; 2019 May; 25(10):3164-3175. PubMed ID: 30674502
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition.
Katayama R; Aoyama A; Yamori T; Qi J; Oh-hara T; Song Y; Engelman JA; Fujita N
Cancer Res; 2013 May; 73(10):3087-96. PubMed ID: 23598276
[TBL] [Abstract][Full Text] [Related]
18. Targeting autophagy potentiates antitumor activity of Met-TKIs against Met-amplified gastric cancer.
Lin X; Peng Z; Wang X; Zou J; Chen D; Chen Z; Li Z; Dong B; Gao J; Shen L
Cell Death Dis; 2019 Feb; 10(2):139. PubMed ID: 30760701
[TBL] [Abstract][Full Text] [Related]
19. Paracrine activation of MET promotes peritoneal carcinomatosis in scirrhous gastric cancer.
Zhao L; Yasumoto K; Kawashima A; Nakagawa T; Takeuchi S; Yamada T; Matsumoto K; Yonekura K; Yoshie O; Yano S
Cancer Sci; 2013 Dec; 104(12):1640-6. PubMed ID: 24118504
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
